A SBIR Phase II contract was awarded to Crinetics Pharmaceuticals in June, 2018 for $1,895,558.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A SBIR Phase I contract was awarded to Crinetics Pharmaceuticals in September, 2017 for $299,510.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Crinetics Pharmaceuticals in February, 2015 for $1,499,966.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Crinetics Pharmaceuticals in April, 2015 for $326,121.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Crinetics Pharmaceuticals in April, 2017 for $2,802,411.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Crinetics Pharmaceuticals in August, 2017 for $297,358.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Crinetics Pharmaceuticals for $282,070.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Crinetics Pharmaceuticals for $296,283.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Crinetics Pharmaceuticals for $2,162,550.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Crinetics Pharmaceuticals for $237,895.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Crinetics Pharmaceuticals for $224,092.0 USD from the U.S. Department of Health & Human Services.